miR-155 antagomir also reduced intestinal barrier impairment and resolved inflammation in a DSS-induced colitis model by inducing the expression of hypoxia-inducible factor 1 (HIF-1), a barrier protective factor involved in mucosal inflammation [85]. The gene discussed is HIF1A; the disease is colitis.